iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical
Company profile
Ticker
IOVA
Exchange
Website
CEO
Maria Fardis
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Amgen • GE Vernova • Gilead Sciences • Apollo Global Management • ADT • Informatica • NIO • Opendoor • GoHealth • BrightSphere Investment ...
Former names
FREIGHT MANAGEMENT CORP, Genesis Biopharma, Inc, Lion Biotechnologies, Inc.
SEC CIK
Corporate docs
Subsidiaries
Iovance Biotherapeutics GmbH, a company • Iovance Biotherapeutics B.V., a company • Iovance Biotherapeutics Manufacturing LLC, a limited liability company • Iovance Biotherapeutics UK Ltd, a limited company • Iovance Biotherapeutics UK SP Ltd, a limited company • Iovance Biotherapeutics Canada Inc., a company ...
IRS number
753254381
IOVA stock data
Latest filings (excl ownership)
8-K
Other Events
9 Aug 24
S-8
Registration of securities for employees
8 Aug 24
S-8
Registration of securities for employees
8 Aug 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
8-K
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
8 Aug 24
8-K
Other Events
28 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
11 Jun 24
8-K
Other Events
3 Jun 24
8-K
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
23 May 24
DEFA14A
Additional proxy soliciting materials
17 May 24
Transcripts
IOVA
Earnings call transcript
2024 Q2
8 Aug 24
IOVA
Earnings call transcript
2024 Q1
9 May 24
IOVA
Earnings call transcript
2023 Q4
28 Feb 24
IOVA
Earnings call transcript
2023 Q3
7 Nov 23
IOVA
Earnings call transcript
2023 Q2
8 Aug 23
IOVA
Earnings call transcript
2023 Q2
8 Aug 23
IOVA
Earnings call transcript
2023 Q1
9 May 23
IOVA
Earnings call transcript
2022 Q4
28 Feb 23
IOVA
Earnings call transcript
2022 Q3
4 Nov 22
IOVA
Earnings call transcript
2022 Q2
5 Aug 22
Latest ownership filings
SC 13G/A
STATE STREET CORP
18 Oct 24
4
Frederick G Vogt
16 Oct 24
4
FINCKENSTEIN FRIEDRICH GRAF
16 Oct 24
4
IGOR BILINSKY
16 Oct 24
4
Frederick G Vogt
5 Sep 24
4
FINCKENSTEIN FRIEDRICH GRAF
5 Sep 24
4
IGOR BILINSKY
5 Sep 24
4
Jean-Marc Bellemin
5 Sep 24
4
Frederick G Vogt
17 Jul 24
4
FINCKENSTEIN FRIEDRICH GRAF
17 Jul 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 235.11 mm | 235.11 mm | 235.11 mm | 235.11 mm | 235.11 mm | 235.11 mm |
Cash burn (monthly) | (no burn) | 5.11 mm | 33.97 mm | 38.27 mm | 32.81 mm | 32.40 mm |
Cash used (since last report) | n/a | 19.19 mm | 127.56 mm | 143.71 mm | 123.20 mm | 121.65 mm |
Cash remaining | n/a | 215.92 mm | 107.54 mm | 91.40 mm | 111.91 mm | 113.46 mm |
Runway (months of cash) | n/a | 42.2 | 3.2 | 2.4 | 3.4 | 3.5 |
Institutional ownership, Q2 2024
86.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 296 |
Opened positions | 74 |
Closed positions | 50 |
Increased positions | 111 |
Reduced positions | 75 |
13F shares | Current |
---|---|
Total value | 1.78 tn |
Total shares | 262.47 mm |
Total puts | 1.66 mm |
Total calls | 1.27 mm |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Quogue Capital | 30.00 mm | $360.90 mm |
Vanguard | 25.95 mm | $208.12 bn |
Perceptive Advisors | 25.93 mm | $207.98 bn |
MHR Fund Management | 24.00 mm | $192.46 bn |
BLK BlackRock | 21.23 mm | $170.23 bn |
STT State Street | 12.63 mm | $101.25 bn |
Avoro Capital Advisors | 11.70 mm | $93.83 bn |
Soleus Capital Management | 7.55 mm | $60.53 bn |
Geode Capital Management | 5.79 mm | $46.42 bn |
Artisan Partners Limited Partnership | 5.11 mm | $40.99 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Oct 24 | Bilinsky Igor | Common Stock | Payment of exercise | Dispose F | No | No | 9.77 | 1,428 | 13.95 k | 55,807 |
14 Oct 24 | Bilinsky Igor | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,813 | 0.00 | 57,235 |
14 Oct 24 | Bilinsky Igor | RSU Common stock | Option exercise | Dispose M | No | No | 0 | 2,813 | 0.00 | 2,813 |
14 Oct 24 | Frederick G Vogt | Common Stock | Payment of exercise | Dispose F | No | No | 9.77 | 8,851 | 86.47 k | 204,245 |
14 Oct 24 | Frederick G Vogt | Common Stock | Option exercise | Acquire M | No | No | 0 | 20,834 | 0.00 | 213,096 |
14 Oct 24 | Frederick G Vogt | RSU Common stock | Option exercise | Dispose M | No | No | 0 | 20,834 | 0.00 | 20,835 |
14 Oct 24 | Finckenstein Friedrich Graf | Common Stock | Payment of exercise | Dispose F | No | No | 9.77 | 1,428 | 13.95 k | 60,727 |
14 Oct 24 | Finckenstein Friedrich Graf | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,813 | 0.00 | 62,155 |
14 Oct 24 | Finckenstein Friedrich Graf | RSU Common stock | Option exercise | Dispose M | No | No | 0 | 2,813 | 0.00 | 2,813 |
3 Sep 24 | Jean-Marc Bellemin | Common Stock | Payment of exercise | Dispose F | No | No | 10.85 | 11,891 | 129.02 k | 29,348 |
News
AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio?
8 Sep 24
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
3 Sep 24
Watching Shares Of Iovance Biotherapeutics; Martin Shkreli Post On X, "$IOVA pretty attractive long idea"
21 Aug 24
Looking Into Iovance Biotherapeutics's Recent Short Interest
16 Aug 24
10 Health Care Stocks With Whale Alerts In Today's Session
12 Aug 24
Press releases
Iovance Biotherapeutics to Present at Upcoming Conferences
3 Sep 24
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
16 Aug 24
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
8 Aug 24
Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
29 Jul 24